RNAi Collaborations & Partnerships

Since inception, Arbutus has fostered collaborations and partnerships with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals Inc., Merck & Co. Inc., Takeda Pharmaceutical Company, Monsanto, and other undisclosed pharmaceutical and biotechnology companies.

Our Partners


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)

Arbutus has granted a license to Alnylam to use Arbutus' LNP technology to enable RNAi therapeutic products. Arbutus will receive milestone and royalty payments as LNP-enabled products are developed and commercialized. Alnylam currently has three LNP-enabled products in human clinical trials: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02.

Spectrum Pharmaceuticals, Inc.

In 2006, Arbutus licensed three liposomal chemotherapy products to Talon Therapeutics: Marqibo® (a liposomal formulation of the chemotherapy drug vincristine); Alocrest (a liposomal formulation of the chemotherapy drug vinorelbine); and, Brakiva (a liposomal formulation of the chemotherapy drug topotecan). In 2013, Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) acquired Talon Therapeutics. Spectrum has launched Marqibo® through its existing hematology sales force. Arbutus receives royalty payments based on Marqibo®’s commercial sales.

 Read more about our Partnered Products here.